What do you find so appealing about ABT's all-oral offering?
Nothing specific in a technical sense; rather, what I find notable is ABT’s use of language in the slide in #msg-68216224.
Unlike small biotech companies, ABT does not typically engage in hyperbole when describing clinical outcomes, so it’s reasonable to infer that ABT is indeed seeing some very impressive results from the all-oral HCV combinations it is testing.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.